Related Experiment Video
Updated: Jul 7, 2026
12:22
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
[Molecular targeted therapy for renal cell carcinoma]
Yoichi Mizutani1, Hiroyuki Nakanishi, Masaaki Mizuno
1Department of Urology, Kyoto Prefectural University of Medicine.
Hinyokika Kiyo. Acta Urologica Japonica
|February 12, 2008
Summary
New molecular targeted therapies offer hope for metastatic renal cell carcinoma (RCC) patients. This review highlights agents effective against advanced kidney cancer, addressing limitations of current treatments.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) represents about 2% of global cancer diagnoses.
- Metastatic RCC presents challenges due to poor response to traditional chemotherapy and radiotherapy.
- Current immunotherapies for RCC show limited efficacy, with response rates around 15-20%.
Purpose of the Study:
- To review emerging molecular targeted therapeutic agents for renal cell carcinoma.
- To discuss novel treatment strategies for metastatic RCC based on recent mechanistic insights.
Main Methods:
- Literature review of recent studies on molecular targeted therapy for RCC.
- Analysis of mechanisms driving RCC growth and therapeutic targets.
Main Results:
- Identification of several new molecular targeted agents showing promise in treating RCC.
- Understanding of specific molecular pathways crucial for RCC development and progression.
Conclusions:
- Molecular targeted therapy represents a promising new avenue for managing metastatic renal cell carcinoma.
- Further research and clinical application of these agents are crucial for improving patient outcomes in advanced kidney cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.